News

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practicesProvides access to a large portion of…

1 year ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially availableProvides rapid clearance of atopic dermatitis signs and symptoms and significant…

1 year ago

Glass House Brands Issues an Open Letter Urging President Biden, Former President Trump and Vice President Harris to De-Schedule Cannabis

LONG BEACH, Calif. and TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…

1 year ago

Venus Concept Announces Regulatory Approval for Venus Bliss MAX in Canada

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology…

1 year ago

Claritas HealthTech Announces Spin-Off of Claritas NucMed Technologies Ltd to Lead Global Delivery of its Suite of Software Solutions in Nuclear Medicine

LONDON and NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Claritas HealthTech (Claritas) a healthcare technology company specializing in advanced…

1 year ago

Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening…

1 year ago

IntoValue, Inc Welcomes Brian Marcotte to Board of Directors

IntoValue, Inc, proudly announces the appointment of Brian Marcotte to its Board of Directors.WASHINGTON, DC / ACCESSWIRE / July 29,…

1 year ago

Avinger to Announce Second Quarter 2024 Results on August 8, 2024

REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the…

1 year ago

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused…

1 year ago